This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F28 (Other nonorganic psychotic disorders) | Special Copayment Reduction: V161 (severe intractable disease, copayment reduction for 5 years after registration) |
| B. Synonyms | Other nonorganic psychosis, chronic hallucinatory psychosis |
| C. Adult onset | Possible first manifestation in adulthood: high — a nonorganic psychosis not corresponding to F20-F25 that can arise at any adult age, but the chronic hallucinatory psychosis form has also been reported to first appear in middle age (30s-50s). |
| 1. History | Established in ICD-10 as a residual category including nonorganic psychoses not corresponding to F20-F25 and F29; the concept of chronic hallucinatory psychosis originated in late 19th-century French psychiatry; criteria for organic exclusion were strengthened by the discovery of autoimmune encephalitis. |
| 2. Causes | Applied after thorough exclusion of organic causes (brain tumor, autoimmune encephalitis, epilepsy, metabolic abnormality, drugs); as nonorganic etiology, dopamine system abnormality, neurodevelopmental vulnerability, and severe psychosocial stress are possible; chronic hallucinatory psychosis is associated with isolated environments and sensory deprivation. |
| 3. Genetics | May partly share the genetic spectrum with F20-F25; specific genetic study data are limited; schizophrenia-spectrum genetic risk burden is observed in some cases. |
| 4. General epidemiology | Epidemiological data for the F28 code alone are very limited; a minority of all psychotic disorders; chronic hallucinatory psychosis is observed relatively commonly in the elderly and in patients with sensory impairment; the range of application of the traditional F28 concept has narrowed with the increase in autoimmune encephalitis. |
| 5. Pathophysiology | Partial dopamine system hyperactivity; hallucinations from sensory deprivation (spontaneous activation of visual and auditory cortex); glutamate abnormality (partial); HPA axis abnormality related to chronic stress; reduced neuroplasticity. |
| 6. Symptoms | Auditory hallucinations (especially prominent in chronic hallucinatory psychosis) or visual hallucinations are the main symptoms; delusions are present but typical first-rank symptoms of schizophrenia are absent or insufficient; independent of mood episodes and not corresponding to F25; negative symptoms are mild or absent. |
| 7. Signs | On psychiatric interview, behavior in response to auditory hallucinations or reports of visual hallucinations; the delusional system is relatively organized; the degree of preserved overall functioning may be better than in schizophrenia; negative symptoms and signs of disorganization are mild; no organic neurological signs. |
| 8. Screening | Excluding organic causes is the top priority; brain MRI, EEG, autoimmune encephalitis panel (anti-NMDAR, anti-LGI1, anti-CASPR2), CSF analysis; blood and urine toxicology, thyroid, and metabolic panels; includes assessment of sensory function (hearing and vision impairment). |
| 9. Diagnosis | After thorough exclusion of organic causes (F00-F09) → confirm criteria for F20-F25 and F29 are not met → apply F28; differentiation from autoimmune encephalitis, drug-induced causes, and temporal lobe epilepsy is most important; confirm the specific clinical criteria of chronic hallucinatory psychosis. |
| 10. Treatment | Second-generation antipsychotics (starting at low doses); in cases related to sensory deprivation, correction of sensory function (hearing aids, glasses) contributes to reducing hallucinations; psychotherapy (supportive, cognitive behavioral therapy); interventions to relieve social isolation; maintenance therapy in a chronic course. |
| 11. Prognosis | Tends to have a better prognosis than schizophrenia; chronic hallucinatory psychosis responds relatively well to treatment but has a risk of chronicity; symptoms can improve when the underlying cause (sensory impairment, isolation) is corrected; functioning is relatively well preserved. |
| 12. Prevention | Early correction of sensory impairment (hearing, vision); prevention of social isolation; avoidance of substance misuse; antipsychotic maintenance therapy; community linkage; stress management. |
| 13. References | Graus F, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016 … and 9 other papers |
Other nonorganic psychotic disorders (F28) is a residual category in the ICD-10 classification system that includes psychotic symptoms, in a state where organic causes have been definitively excluded, that also do not correspond to F20 (schizophrenia), F21 (schizotypal disorder), F22 (persistent delusional disorders), F23 (acute and transient psychotic disorders), F24 (induced delusional disorder), F25 (schizoaffective disorders), or F29 (unspecified nonorganic psychosis). In ICD-10, "chronic hallucinatory psychosis" is specified as the representative example of this category.
The historical origin of chronic hallucinatory psychosis can be found in late 19th-century French psychiatry. In 1852, Legrand du Saulle described a chronic hallucinatory state without persecutory delusions, and later Séglas established the term "psychose hallucinatoire chronique." This concept has long been used in the French psychiatric tradition as a clinical entity separate from schizophrenia, and was described as having onset mainly in middle age or later, with hallucinations as the main symptom, mild disorganization or negative symptoms, and relatively preserved personality.
However, in English-language psychiatry there was a strong tendency to understand "chronic hallucinatory psychosis" as a variant of schizophrenia, and the inclusion of this concept as an example of F28 in ICD-10 reflects the influence of the French psychiatric tradition. The DSM classification system has no corresponding independent category, and it is classified as schizophrenia or other specified schizophrenia spectrum disorder.
One of the most important historical developments in the F28 classification is the discovery of autoimmune encephalitis. After Dalmau et al. first reported anti-NMDAR antibody encephalitis in 2007, it became clear that many cases that would previously have been classified as "nonorganic psychosis" were in fact autoimmune encephalitis. This dramatically highlighted the importance of excluding organic causes before applying F28. In particular, anti-NMDAR antibody encephalitis shows typical schizophrenia-like symptoms such as auditory hallucinations, delusions, and disorganized behavior, so there is a high risk of initial misdiagnosis as nonorganic psychosis.
In ICD-11 (2022), the boundaries of the category corresponding to F28 were reconsidered, and there is discussion of strengthening the criteria for organic exclusion further in light of new medical knowledge such as autoimmune encephalitis. In Korean clinical practice, the F28 code is applied as other nonorganic psychotic disorders, and registration under Special Copayment Reduction V161 is possible.
A special form of chronic hallucinatory psychosis is auditory hallucinations associated with hearing impairment. The phenomenon of auditory hallucinations occurring in patients with hearing impairment (especially age-related hearing loss) is explained by spontaneous activation of the auditory cortex due to sensory deprivation, and this is clinically important in that hearing aids may be a more effective intervention than antipsychotics.
The cause of other nonorganic psychotic disorders (F28) is, by definition, a category applied after organic (brain-organic, somatic-organic) causes have been thoroughly excluded, so nonorganic etiological elements are central.
Necessity of excluding organic causes: The following organic causes must be excluded before a diagnosis of F28. Neurological causes include brain tumor, temporal lobe epilepsy, cerebrovascular disease, multiple sclerosis, autoimmune encephalitis (anti-NMDAR antibody, anti-LGI1 antibody, anti-CASPR2 antibody, anti-GABA-B antibody, etc.), and neurodegenerative disease (dementia with Lewy bodies). Metabolic and endocrine causes include thyroid dysfunction, adrenal insufficiency (Addison disease), hypoglycemia, electrolyte abnormalities, hepatic encephalopathy, and uremia. Drug-induced causes include steroids, antiparkinsonian agents (levodopa), anticholinergics, quinolone antibiotics, interferon, and some anticancer drugs. Substance-related causes include cannabis, cocaine, methamphetamine, synthetic cannabinoids, and alcohol withdrawal.
Sensory deprivation and the development of hallucinations: Sensory deprivation is being studied as one of the main causes of chronic hallucinatory psychosis. Hearing impairment (especially age-related hearing loss) can cause spontaneous activation due to reduced input to the auditory cortex, resulting in auditory hallucinations. This is understood as musical hallucinations or the auditory analogue of Charles Bonnet syndrome. Visual impairment (especially macular degeneration) and Charles Bonnet syndrome (visual hallucinations) are likewise explained by a similar sensory deprivation mechanism.
Social isolation and psychosocial factors: Social isolation, immigration experience, language barriers, and chronic loneliness are known to contribute to the development of hallucinations. The aberrant salience attribution theory explains this: in a state of social isolation, reduced external stimuli can lead to misattribution to reality of internal stimuli (spontaneous neural activation).
Partial abnormality of the dopamine system: Compared with schizophrenia, dopamine system abnormality in F28 cases is understood to be more limited or partial. This is consistent with the clinical characteristics of mild negative symptoms, less prominent disorganization symptoms, and relatively preserved personality. The treatment response to antipsychotics may be similar to that in schizophrenia, but lower doses are sometimes sufficient.
Specific research on the genetics of other nonorganic psychotic disorders (F28) is very limited. This is because F28 is a residual category including heterogeneous clinical cases and has rarely been analyzed separately in large-scale genomic studies.
Possible partial sharing of schizophrenia-spectrum genetic risk: Some F28 cases, especially the chronic hallucinatory psychosis form, may partly share genetic risk variants of the schizophrenia spectrum. When auditory hallucinations and delusions are the main symptoms, dopamine D2 receptor-related genes, serotonin receptor genes, the COMT Val158Met polymorphism, and others may be relevant.
Genetic vulnerability to sensory deprivation-related hallucinations: The development of hallucinations related to hearing or visual impairment can be understood as an interaction between genetic vulnerability to the sensory impairment (e.g., DFNB genes, macular degeneration-related genes) and central nervous system plasticity-related genes. The BDNF Val66Met polymorphism is being studied as increasing vulnerability in the process of neural reorganization after sensory deprivation.
Principle of application after excluding autoimmune encephalitis and genetic considerations: Autoimmune encephalitis occurs in individuals with immune vulnerability associated with HLA gene polymorphisms, so an autoimmune panel must be completed before a diagnosis of F28. Anti-NMDAR antibody encephalitis has been reported to be associated with HLA-DQ polymorphisms. In F28 cases applied after autoimmune encephalitis has been excluded, such autoimmune genetic risk is not relevant.
Limits of clinical genetic counseling: Genetic counseling in the diagnosis of F28 focuses on providing information about general psychosis-spectrum family risk and preparing a relapse prevention plan rather than on specific gene risk. When sensory impairment (hearing, vision) is a causal factor, separate counseling on the genetic causes of that sensory impairment may be needed.
Independent epidemiological data for other nonorganic psychotic disorders (F28) are very limited. As a residual category, this code is used infrequently and is rarely analyzed separately in large-scale epidemiological studies.
Epidemiology of chronic hallucinatory psychosis: Chronic hallucinatory psychosis tends to have onset in middle age (40s-60s) or later, and French psychiatric literature indicates it is slightly more common in women. It is characterized by later age of onset than schizophrenia and relatively good preservation of social functioning and personality. There are no accurate data on prevalence, but it accounts for a minority of all psychotic spectrum disorders.
Epidemiology of sensory impairment-related hallucinations: Auditory hallucinations associated with hearing impairment are relatively common in the elderly population with hearing loss, and musical hallucinations are reported in about 1-3% of patients with severe hearing loss. Charles Bonnet syndrome, associated with visual impairment, is reported in about 10-15% of patients with severe visual impairment, and both phenomena are markedly more common in the elderly population. Such sensory deprivation-related hallucinations can be classified under the related medical condition (F06.0, organic hallucinosis) rather than F28, so the boundary with the F28 category is unclear.
Change in the scope of F28 application following the discovery of autoimmune encephalitis: With the introduction of autoimmune encephalitis panel testing into clinical practice after 2007, a considerable number of patients who would previously have been classified as F28 were reclassified as autoimmune encephalitis. This means that the actual scope of application of F28 has become narrower than in the past, and emphasizes the importance of thorough exclusion of organic causes.
Current use in Korea: In Health Insurance Review & Assessment Service data, the F28 code is used at a relatively low frequency, and in clinical practice it is sometimes applied provisionally to atypical cases of the schizophrenia spectrum or to early cases in which excluding organic causes is difficult. It is applicable for Special Copayment Reduction V161 registration.
The pathophysiology of other nonorganic psychotic disorders (F28) is understood as nonorganic neurobiological mechanisms that cause psychotic symptoms (mainly hallucinations and delusions) once organic causes have been excluded.
Partial hyperactivity of the dopamine system: As in schizophrenia, mesolimbic dopamine hyperactivity is the basis of auditory hallucinations and delusions. However, in F28 cases this abnormality is understood to be less widespread or more localized than in schizophrenia, which is consistent with the clinical characteristics of mild negative and disorganization symptoms. The effectiveness of D2 blockade by antipsychotics for symptom control supports this mechanism.
Sensory deprivation and spontaneous cortical activation: In chronic hallucinatory psychosis and sensory impairment-related hallucinations, reduced sensory input to the auditory cortex (auditory hallucinations) or visual cortex (visual hallucinations) increases cortical excitability and induces spontaneous activation. A "release" mechanism has been proposed in which spontaneous neural activation, normally suppressed by external sensory input, is not inhibited and leads to the hallucinatory experience. This is supported by the occurrence of short-term hallucinations in healthy individuals in sensory deprivation experiments (anechoic dark room).
Aberrant salience attribution: An abnormality of the cognitive process of attributing internal spontaneous neural activation to external real causes is proposed as the mechanism of delusion formation. The ability to attribute normally that "this thought/experience comes from within me" is impaired, so spontaneous internal activation is experienced as "external reality." This mechanism applies to both auditory hallucinations and delusions.
HPA axis and stress response abnormalities: Chronic stress and social isolation hyperactivate the HPA axis, affecting the dopamine system and increasing vulnerability to hallucinations. In the elderly population, social isolation combined with age-related changes in the dopamine system may act together to contribute to the manifestation of chronic hallucinatory psychosis.
Reduced neuroplasticity: In chronic hallucinatory psychosis, reduced hippocampal neuroplasticity associated with decreased BDNF may contribute to chronicity of hallucinations and treatment resistance. Antipsychotic treatment and participation in social activities are understood to restore neuroplasticity and contribute to symptom improvement.
The symptoms of other nonorganic psychotic disorders (F28) are characterized by an atypical pattern in which psychotic symptoms (mainly hallucinations and delusions) appear but do not fully meet the typical symptom criteria defined in F20-F25.
Symptoms of chronic hallucinatory psychosis: Auditory hallucinations are the most prominent symptom. Auditory hallucinations appear in various forms such as conversing voices, commanding voices, and commenting voices, and may resemble those of schizophrenia. However, in chronic hallucinatory psychosis, a characteristic feature is that personality and social functioning are relatively well preserved even though the auditory hallucinations persist for a long time (chronically). Delusions mainly may be persecutory or of reference, but tend to be less bizarre and more organized than in schizophrenia. First-rank symptoms of schizophrenia (thought insertion, withdrawal, and broadcasting; passivity experiences) are not prominent. Negative symptoms (blunted affect, avolition, alogia) are mild or absent, and personality and occupational functioning are relatively maintained. Disorganized thinking and behavior are not pervasive.
Symptoms of sensory impairment-related hallucinations: Hallucinations related to hearing impairment are mainly expressed as music, voices (especially songs or familiar phrases), and repetitive sounds. Patients often are not convinced that the sounds come from outside (non-fixed), or experience a decrease in the hallucinations after using hearing aids. Visual hallucinations (Charles Bonnet syndrome) are formed visual hallucinations of people, animals, geometric patterns, and so on, and patients often experience them while knowing they are not real (insight preserved).
Symptom differences from F20-F25: In F28 cases, the typical features of schizophrenia (first-rank symptoms, severe disorganization, extensive negative symptoms, marked functional decline) are absent or insufficient, and the specific relationship with mood episodes required for schizoaffective disorder (F25) is also not met. Distinction from persistent delusional disorder (F22) lies in the prominence of hallucinations and the different content and structure of the delusions.
The clinical signs of other nonorganic psychotic disorders (F28) are generally milder than in schizophrenia, and especially in the chronic hallucinatory psychosis form, personality and functioning are relatively well preserved.
Psychiatric interview findings: Behavior in response to auditory hallucinations (eye movements responding to internal stimuli, talking to oneself, a listening posture) is observed. Delusional thought content is revealed, but is often less bizarre or disorganized than in schizophrenia. Speech fluency and logical connectedness of thought are relatively maintained. The ego boundary is more stable than in schizophrenia, and thought insertion or passivity is not reported. Insight is not completely lost, and some patients have partial awareness, saying that the auditory hallucinations are "strange" or that they "do not know."
Findings of preserved functioning: Basic functioning in conversation and social interaction is maintained. Self-care ability (hygiene, eating, clothing) is maintained better than in schizophrenia. Occupational functioning is partly maintained in some cases. In chronic hallucinatory psychosis, preserved consistency of personality is characteristic.
Physical examination findings: There should be no organic neurological signs (focal neurological deficit, cognitive decline, movement disorder). Sensory function testing (hearing test, vision test) is important, and when sensory impairment is confirmed, evaluate whether it is a causal factor of the hallucinations. Confirm the absence of thyroid abnormalities and autoimmune signs on physical examination.
Rating scales: The PANSS (focused on positive symptoms), BPRS, and Global Assessment of Functioning (GAF) are applied. Compared with schizophrenia, the negative symptom subscale score tends to be lower and the global functioning score higher. Suicide risk assessment (C-SSRS) is also performed.
In other nonorganic psychotic disorders (F28), the key to screening is thorough exclusion of organic causes. Because F28 is a diagnosis applied after organic causes have been sufficiently excluded, tests to exclude organic causes come first.
Essential tests to exclude organic causes: Brain MRI (to exclude brain tumor, temporal lobe lesions, cerebrovascular disease, demyelinating disease), EEG (to exclude temporal lobe epilepsy), autoimmune encephalitis panel (anti-NMDAR antibody, anti-LGI1 antibody, anti-CASPR2 antibody, anti-GABA-B antibody, anti-AMPAR antibody, VGKC complex antibody), and CSF analysis (cell count, protein, glucose, autoimmune markers) are essential. Blood tests include CBC, electrolytes, liver function, kidney function, blood glucose, thyroid function (TSH, FT4), adrenal function (cortisol, ACTH), vitamin B12, folate, RPR, HIV, and ANA (antinuclear antibody). A urine toxicology test must also be performed.
Sensory function assessment: Perform an audiogram to assess the degree of hearing impairment. Assess visual impairment through an ophthalmologic examination (visual acuity, macular degeneration, glaucoma, etc.). When sensory impairment is confirmed, a clinical trial of observing changes in hallucinations after applying assistive devices (hearing aids, glasses) is useful to determine whether it is a causal factor of the hallucinations.
Structured clinical interview: Systematically review the F20-F25 and F29 criteria. Use the SCID-5 or MINI to confirm and exclude the criteria for schizophrenia, schizoaffective disorder, delusional disorder, bipolar disorder, and major depressive disorder.
The diagnosis of other nonorganic psychotic disorders (F28) is made through a thorough process of exclusion, and the following stepwise approach is recommended.
Step 1: Exclude organic causes: Exclude all causes falling under F00-F09 (organic, including symptomatic, mental disorders). In particular, exclude autoimmune encephalitis, temporal lobe epilepsy, drug-induced psychosis, and metabolic abnormalities first. Complete brain MRI, EEG, autoimmune panel, and blood and urine toxicology tests.
Step 2: Review the F20-F25 criteria: Review the criteria for schizophrenia (F20) (first-rank symptoms, negative symptoms, global functional decline, persistence of 6 months or more) and confirm they are not met. Check the criteria for schizoaffective disorder (F25) (accompanying mood episodes) and confirm they are not met. Review the criteria for persistent delusional disorder (F22), acute and transient psychotic disorders (F23), and schizotypal disorder (F21).
Step 3: Apply F28: Apply F28 when organic causes have been excluded and psychotic symptoms (mainly hallucinations and delusions) not corresponding to F20-F25 persist. When the characteristics of chronic hallucinatory psychosis (onset in middle age, auditory hallucination predominance, preserved personality, maintained functioning) are confirmed, specify this.
Key points of differential diagnosis: Autoimmune encephalitis may not be completely excluded even if antibody tests are negative, so if there is an atypical clinical course (abrupt change, accompanying cognitive decline, movement abnormalities), a neurology consultation must be requested. Differentiation between chronic hallucinatory psychosis and schizophrenia comprehensively considers age of onset, presence of negative symptoms, degree of preserved social functioning, and preservation of personality.
Treatment of other nonorganic psychotic disorders (F28) aims at controlling the main symptoms, hallucinations and delusions, and also includes direct intervention on causal factors such as correction of sensory impairment where necessary.
Antipsychotic treatment: Second-generation antipsychotics are the first choice. In chronic hallucinatory psychosis they may be effective at lower doses than in schizophrenia, and in elderly patients treatment is started especially at a low dose and increased slowly. Risperidone, quetiapine, and olanzapine are commonly used. Quetiapine is preferred because it has relatively fewer extrapyramidal adverse effects in the elderly.
Correction of sensory function: For auditory hallucinations associated with hearing impairment, prescribing hearing aids or cochlear implant surgery can contribute directly to reducing the hallucinations. For visual impairment (Charles Bonnet syndrome), vision correction (surgery, glasses, low-vision aids) can reduce visual hallucinations. Because such sensory function correction may be a more effective intervention than antipsychotics, accurate assessment and correction of sensory impairment is the priority.
Psychosocial treatment: Supportive psychotherapy is the foundation, and cognitive behavioral therapy (CBT) is applied when the patient partly recognizes the strangeness of the hallucinatory experience. An acceptance-based approach to auditory hallucinations (ACT, Acceptance and Commitment Therapy) is effective in some patients. Interventions to relieve social isolation (social activity programs, linkage to community services) are important for the prevention and treatment of chronic hallucinatory psychosis.
Maintenance therapy in a chronic course: When symptoms have become chronic, long-term maintenance drug treatment is needed. Treatment adherence is secured with long-acting injectables (LAI). The occurrence of new physical illness (especially neurological disease) is monitored through regular reassessment of organic causes.
The prognosis of other nonorganic psychotic disorders (F28) tends to be better overall than that of schizophrenia, but is difficult to generalize owing to the heterogeneity of cases.
Prognosis of chronic hallucinatory psychosis: The response to antipsychotic treatment is relatively good, and the intensity and frequency of auditory hallucinations often decrease. However, partial control (a state in which auditory hallucinations lessen but do not disappear completely) is a more common course than complete remission. Because personality and social functioning are better preserved than in schizophrenia, quality of life is relatively good.
Prognosis of sensory impairment-related hallucinations: When sensory function is corrected (hearing aids, vision correction), the hallucinations can markedly decrease or disappear, so the prognosis is good. When correction of sensory function is difficult (severe hearing loss, severe macular degeneration), the course is chronic.
Factors worsening prognosis: Antipsychotic nonadherence, persistent social isolation, comorbid substance misuse, and progression of an underlying neurological disease are associated with worse prognosis. In elderly patients, adverse effects of antipsychotics (falls, metabolic abnormalities, accelerated cognitive decline) can negatively affect prognosis.
Risk of misdiagnosis and reassessment for autoimmune encephalitis: In a patient classified as F28, if the treatment response is poor or an atypical clinical course appears (added cognitive decline, development of movement abnormalities), autoimmune encephalitis should be reassessed. When autoimmune encephalitis is identified late, dramatic improvement is possible with immunotherapy (corticosteroids, immunoglobulin, plasma exchange, rituximab).
Prevention of other nonorganic psychotic disorders (F28) aims at correction of causal factors, relapse prevention, and maintenance of functioning.
Early correction of sensory impairment: Early detection of hearing impairment and prescribing hearing aids is the most effective primary prevention strategy for preventing auditory hallucinations in the elderly. Sensory impairment is detected early and corrected through regular hearing and vision tests. Treatment of progressive visual impairment such as macular degeneration and glaucoma prevents the development of visual hallucinations.
Prevention of social isolation: Participation in community activities, use of elderly welfare services, and regular social interaction to relieve social isolation contribute to preventing chronic hallucinatory psychosis. Strengthening community support for immigrant groups, the elderly, and the socially vulnerable is important.
Antipsychotic maintenance therapy and relapse prevention: Relapse is prevented through maintenance drug treatment after stabilization of acute-phase symptoms. Adherence is secured with LAI. Regular outpatient follow-up and symptom monitoring are important.
Avoiding substance misuse and continued monitoring for organic causes: Education is provided on avoiding substance misuse (cannabis, alcohol, stimulants). New organic causes (autoimmune disease, neurological disease) are detected early through regular physical health checkups. When treatment response is poor, reassessment of organic causes must be performed.
Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404. DOI: 10.1016/S1474-4422(15)00401-9. PMID: 26906964.
Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61(1):25-36. DOI: 10.1002/ana.21050. PMID: 17262855.
Cole MG, Dowson L, Dendukuri N, Belzile E. The prevalence and phenomenology of auditory hallucinations among elderly subjects attending an audiology clinic. Int J Geriatr Psychiatry. 2002;17(5):444-452. DOI: 10.1002/gps.618. PMID: 11994936.
Teunisse RJ, Cruysberg JR, Hoefnagels WH, et al. Visual hallucinations in psychologically normal people: Charles Bonnet's syndrome. Lancet. 1996;347(9004):794-797. DOI: 10.1016/s0140-6736(96)90869-7. PMID: 8622352.
Berrios GE, Brook P. The Charles Bonnet syndrome and the problem of visual perceptual disorders in the elderly. Age Ageing. 1982;11(1):17-23. DOI: 10.1093/ageing/11.1.17. PMID: 7081442.
van der Gaag M, Valmaggia LR, Smit F. The effects of individually tailored formulation-based cognitive behavioural therapy in auditory hallucinations and delusions: a meta-analysis. Schizophr Res. 2014;156(1):30-37. DOI: 10.1016/j.schres.2014.03.016. PMID: 24721526.
Heckers S, Barch DM, Bustillo J, et al. Structure of the psychotic disorders classification in DSM-5. Schizophr Res. 2013;150(1):11-14. DOI: 10.1016/j.schres.2013.04.039. PMID: 23707641.
Dudley R, Aynsworth C, Bhatt M, et al. A systematic review of the experience of psychotic-like phenomena in multisensory loss (Charles Bonnet syndrome) and sensory deprivation. Clin Psychol Rev. 2019;73:101777. DOI: 10.1016/j.cpr.2019.101777. PMID: 31476636.
Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry. 2003;160(1):13-23. DOI: 10.1176/appi.ajp.160.1.13. PMID: 12505793.
Murru A, Pacchiarotti I, Nivoli AM, et al. What we know and what we don't know about the treatment of schizoaffective disorder. Eur Neuropsychopharmacol. 2011;21(9):680-690. DOI: 10.1016/j.euroneuro.2011.03.010. PMID: 21482081.